PKM and melanoma: Twenty participants with advanced TYRP1-positive melanoma (cutaneous, n = 10; uveal, n = 6; mucosal, n = 3; unknown primary, n = 1) were enrolled and received TYRP1-TCB (participant characteristics are presented in Table 1); 19 of these participants had received at least one prior systemic therapy that included an anti-PD-1 antibody.